icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

Amgen Stock Plummets 4.99% Amid Profitability Concerns Despite FDA Approval

Mover TrackerTuesday, Apr 8, 2025 6:50 pm ET
1min read

Amgen Inc. (AMGN) has caught the attention of investors recently with significant fluctuations in its stock performance. Notably, on April 4, the company's stock price fell by 4.99%, hitting a new low since 2025. This volatility raises the question of what underlying factors are causing such dramatic price movements for the biotech giant.

On April 3, 2025, amgen announced the approval of its drug Uplizna (Inebilizumab) by the U.S. Food and Drug Administration (FDA) for treating IgG4-related disease (IgG4-RD). This development is a positive one, considering IgG4-RD is a chronic, debilitating immunologically mediated inflammatory disease with a high unmet clinical need. The drug promises to substantially improve patient quality of life. However, financial records indicate that while Amgen's 2024 revenue grew to $33.42 billion, marking an 18.57% increase, its net income for shareholders decreased significantly by 39.11%, to just $4.09 billion. Such a decline in profitability may cause investors to question its future performance.

Amgen has long been committed to innovation in the biotech sector, aiming to address unmet medical needs through new pharmaceuticals. Despite focusing on innovation, the company is challenged by profitability pressures. These stem from substantial R&D expenses and fierce competition within the biotech industry. In light of these challenges, investors may approach Amgen's long-term strategy with caution.

Additionally, Amgen is set to release its first-quarter financial results on May 1, 2025. This upcoming report is eagerly anticipated, as it will provide further insights into the effectiveness of the company's new drug development and market expansion efforts, as well as its strategies in coping with industry competition. For investors, this pivotal disclosure could aid in assessing the company's future trajectory.

Investors considering Amgen should focus on several aspects: firstly, the company’s competitive strength in a dynamic industry environment and its new drug's market acceptance. Secondly, they should closely monitor the forthcoming financial report data, which will shed more light on Amgen's potential for profitability in the future. Lastly, given the nature of the biotechnology sector, investors must remain vigilant about market volatility and be prepared to adjust their portfolios as necessary to mitigate risk.

Comments

Add a public comment...
Post
User avatar and name identifying the post author
anonymus431
04/08
Amgen's R&D expenses are a major concern.
0
Reply
User avatar and name identifying the post author
maximalsimplicity
04/08
FDA approval boost temporary, watch fundamentals closely.
0
Reply
User avatar and name identifying the post author
NavyGuyvet
04/08
Biotech sector volatility is just part of the game.
0
Reply
User avatar and name identifying the post author
Local-Store-491
04/08
AMGN's drop might scare noobs, but long-term plays often bounce back. Patience pays in biotech rollercoasters.
0
Reply
User avatar and name identifying the post author
Max-Pencil
04/08
Damn!!Those $AMGN whale-sized options block were screaming danger! � Closed positions just in time profiting more than $391
0
Reply
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App